Common Pill May Help Stroke Survivors Manage High Blood Pressure

Stroke survivors struggle against persistent hypertension, but a low-cost medication offers a fresh avenue for reducing blood pressure after a stroke, Fox News reported.

Researchers presented the REDUCE trial findings at the American Heart Association’s Scientific Sessions in Chicago. The study tested whether adding spironolactone, commonly known as a water pill, could help patients whose blood pressure remained elevated despite standard treatment.

Participants were split into two groups. One added spironolactone to their regular post-stroke care, while the other continued with standard treatment alone.

“Lowering blood pressure is the most important step in preventing another stroke, yet many survivors struggle to reach recommended blood pressure targets after a stroke,” said Dr. Jordana Cohen, an associate professor of medicine and epidemiology at the University of Pennsylvania, in a news release.

Common Pill May Help Stroke Survivors Manage High Blood Pressure
Photo: EMJ

Blood Pressure Drops in Trial

Researchers tracked home blood pressure readings over six months. After three months, the top blood pressure number dropped by nearly eight points on average among patients taking spironolactone compared to the control group, recording about 126 mm Hg versus 133 mm Hg.

52% of patients taking the medication reached the recommended blood pressure goal of less than 130/80, compared to 30% of those receiving usual care.

“When spironolactone was added to post-stroke care, we saw a meaningful drop in blood pressure that may lower the risk of future strokes and heart attacks,” Cohen added.

At the same conference, researchers shared broader data on blood pressure targets from concurrent international trials. The OPTIMAL-STROKE trial, published in the New England Journal of Medicine and reported by EMJ, evaluated 4,368 adults in Brazil with a history of ischemic stroke or transient ischemic attack.

That study found that intensive treatment targeting a systolic blood pressure below 120 mm Hg reduced major cardiovascular events by 21% over a median follow-up of 3.9 years, compared to a standard target below 140 mm Hg.

FDA approves new medicine that can help those who have survived strokes — WQAD News 8

Intensive Blood Pressure Reduction Increases Renal Complication Risks

Intensive blood pressure reduction brings trade-offs that physicians must manage. The OPTIMAL-STROKE trial reported that intensive treatment increased composite renal complications, such as a sustained decline in estimated glomerular filtration rate, affecting 3.9% of intensive-treatment patients compared to 2.2% in the standard group, Medscape noted.

Similarly, spironolactone causes the body to retain potassium, requiring careful monitoring by clinicians. Dr. Alfred Joshua, a California-based board-certified emergency physician not involved in the REDUCE trial, said that high potassium develops silently and poses risks for patients with kidney issues or those taking specific medications.

“We already know that controlling blood pressure lowers the risk of another stroke,” Joshua told Fox News Digital. “This study measured blood pressure, so whether adding spironolactone leads to fewer repeat strokes is still an open question.”

Gty doctor patient blood pressure
Photo: Medscape

The REDUCE trial ended early with 160 participants instead of the planned 200, and about 15% lacked three-month blood pressure readings. Patients taking spironolactone used slightly more blood pressure medications overall than the control group.

Questions About Spironolactone

  • The trial measured blood pressure reduction rather than clinical endpoints like recurrent stroke, leaving the direct prevention of subsequent events unproven.
  • High potassium levels and dizziness caused by excessive blood pressure drops are the main risks tracked by clinicians.
  • Survivors with persistently high readings at home are advised to bring logs to their clinician to discuss medication adjustments.

The OPTIMAL-DIABETES trial, published in the New England Journal of Medicine, found a neutral effect on cardiovascular events when targeting a systolic blood pressure below 120 mm Hg in patients with type 2 diabetes.

“Managing blood pressure in stroke patients is incredibly difficult, I say as somebody who has to own that as a clinician,” said Gisele Sampaio of the Federal University of Sao Paulo, as reported by STAT.